Diamyd Medical AB (Nasdaq First North Growth:DMYDB), a developer of precision medicine therapies for type 1 diabetes, reported on Wednesday that a longer term follow-up of participants in the DIAGNODE-2 trial of its diabetes vaccine Diamyd indicated a continuing effect from the treatment.
Actively treated individuals carrying the genetically defined haplotype HLA DR3-DQ2 followed their expected trajectory from 15 to 24 months, showing no indication of diminishing treatment effect compared to their progression up to to 15 months, Diamyd said. Additionally, there was no difference in adverse events between actively treated and placebo treated individuals at 24 months.
The vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma